Answers are grounded in this paper and cite their sources.
The combination of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) is widely practiced for appendiceal, colorectal, gastric, and ovarian cancers with isolated peritoneal metastasis as well as for primary peritoneal cancer. The aim of this report is to explain the rationale and available techniques for CRS and IPC, and to highlight disease-specific considerations that should be taken into account when evaluating potential candidates for CRS and IPC.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: